

Table 2. Mean changes from baseline of metabolic and other parameters with phentermine and controlled-release topiramate (PHEN/TPM CR) treatment and placebo

Metabolic Parameter		Placebo	Low Or Mid Dose	Full Dose
Blood pressure (mm Hg)	SBP	-3.2 to 0.9	-4.7 to -1.8	-5.6 to -2.9
	DBP	-3.9 to 0.4	-3.7 to -0.1	-3.8 to -1.5
FBG (mmol/L)		0.13 to 3.7	-0.01 to 0.8	-1.2 to -0.07
Glycated hemoglobin (%)		0.1 to 0.2	0 to 0.01	-0.1 to 0
TG (%)		0.4 to 9.1	-12.5 to -8.6	-13.7 to -5.2
LDL cholesterol (%)		-10.7 to -4.1	-7.7 to -3.7	-8.4 to -5.6
HDL cholesterol (%)		0 to 4.7	5.2 to 7.3	3.5 to 11.9
Total cholesterol (%)		-3.5 to -3.3	-5.4 to -4.9	-6.3 to -6
Waist circumference (cm)		-3.6 to -2.4	-9.8 to -5.6	-10.9 to -9.2

All the changes were statistically significant between active treatment and placebo except for LDL-C and in some trials for Blood Pressure, mainly DBP. SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, FBG: Fasting Blood Glucose, TG: Triglycerides, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein.